Everolimus (RAD001): First systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex

Future Oncology

Volumn 8, Issue 12, 2012, Pages 1515-1523

  Józwiak, Sergiusz ^a   Stein, Karen ^b   Kotulska, Katarzyna ^a  

^a CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

everolimus; mTOR inhibition; subependymal giant cell astrocytomas; tuberous sclerosis complex; tumor volume

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; EVEROLIMUS; MULTIDRUG RESISTANCE PROTEIN; RAPAMYCIN;

AMENORRHEA; ANTINEOPLASTIC ACTIVITY; CLINICAL FEATURE; CONVULSION; DERMATITIS; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FEVER; GENE MUTATION; HUMAN; HYPERLIPIDEMIA; INOPERABLE CANCER; MOUTH ULCER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; STOMATITIS; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; TREATMENT RESPONSE; TUBEROUS SCLEROSIS; TUMOR VOLUME; UPPER RESPIRATORY TRACT INFECTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ASTROCYTOMA; CLINICAL TRIALS AS TOPIC; HUMANS; ORAL ULCER; SIROLIMUS; STOMATITIS; TOR SERINE-THREONINE KINASES; TUBEROUS SCLEROSIS;

EID: 84871185406     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.146     Document Type: Review

References (50)

1. Osborne JP, Fryer A, Webb D. Epidemiology of tuberous sclerosis. Ann. N. Y. Acad. Sci. 615, 125-127 (1991
2. Franz DN, Bissler JJ, McCormack FX. Tuberous sclerosis complex: Neurological, renal and pulmonary manifestations. Neuropediatrics 41, 199-208 (2010
3. Schwartz RA, Fernandez G, Kotulska K, Jozwiak S. Tuberous sclerosis complex: Advances in diagnosis, genetics, and management. J. Am. Acad. Dermatol. 57, 189-202 (2007
4. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet 372, 657-668 (2008
5. Borkowska J, Schwartz RA, Kotulska K, Jozwiak S. Tuberous sclerosis complex: Tumors and tumorigenesis. Int. J. Dermatol. 50, 13-20 (2011
6. Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference: Revised clinical diagnostic criteria. J. Child. Neurol. 13, 624-628 (1998
7. Jozwiak S, Schwartz RA, Janniger CK, Bielicka-cymerman J. Usefulness of diagnostic criteria of tuberous sclerosis complex in pediatric patients. J. Child. Neurol. 15, 652-659 (2000
8. Goh S, Butler W, Thiele EA. Subependymal giant cell tumors in tuberous sclerosis complex. Neurology 63, 1457-1461 (2004
9. Buccoliero AM, Franchi A, Castiglione F et al. Subependymal giant cell astrocytoma (SEGA): Is it an astrocytoma? Morphological, immunohistochemical and ultrastructural study. Neuropathology 29, 25-30 (2009
10. Cuccia V, Zuccaro G, Sosa F, Monges J, Lubienieky F, Taratuto AL. Subependymal giant cell astrocytoma in children with tuberous sclerosis. Childs Nerv. Syst. 19, 232-243 (2003
11. Adriaensen ME, Schaefer-Prokop CM, Stijnen T, Duyndam DA, Zonnenberg BA, Prokop M. Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature. Eur. J. Neurol. 16, 691-696 (2009
12. Grajkowska W, Kotulska K, Jurkiewicz E et al. Subependymal giant cell astrocytomas with atypical histological features mimicking malignant gliomas. Folia Neuropathol. 49, 39-46 (2011
13. Sancak O, Nellist M, Goedbloed M et al. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: Genotype- phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex. Eur. J. Hum. Genet. 13, 731-741 (2005
14. Huang J, Manning BD. The TSC1-TSC2 complex: A molecular switchboard controlling cell growth. Biochem. J. 412, 179-190 (2008
15. Kandt RS, Haines JL, Smith M et al. Linkage of an important gene locus for tuberous sclerosis to a chromosome 16 marker for polycystic kidney disease. Nat. Genet. 2, 37-41 (1992
16. van Slegtenhorst M, de Hoogt R, Hermans C et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 277, 805-808 (1997
17. European Chromosome 16 Tuberous Sclerosis Consortium: Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75, 1305-1315 (1993
18. Jozwiak J, Jozwiak S, Wlodarski P. Possible mechanisms of disease development in tuberous sclerosis. Lancet Oncol. 9, 73-79 (2008
19. Jozwiak S, Kwiatkowski D, Kotulska K et al. Tuberin and hamartin expression is reduced in the majority of subependymal giant cell astrocytomas in tuberous sclerosis complex consistent with a two-hit model of pathogenesis. J. Child. Neurol. 19, 102-106 (2004
20. Roszkowski M, Drabik K, Barszcz S, Jozwiak S. Surgical treatment of intraventricular tumors associated with tuberous sclerosis. Childs Nerv. Syst. 11, 335-339 (1995
21. Ekici MA, Kumandas S, Per H et al. Surgical timing of the subependymal giant cell astrocytoma (SEGA) with the patients of tuberous sclerosis complex. Turk. Neurosurg. 21, 315-324 (2011
22. Sun P, Kohrman M, Liu J, Guo A, Rogerio J, Krueger D. Outcomes of resecting subependymal giant cell astrocytoma (SEGA) among patients with SEGA-related tuberous sclerosis complex: A national claims database analysis. Curr. Med. Res. Opin. 28, 657-663 (2012
23. Sun P, Krueger D, Liu J, Guo A, Rogerio J, Kohrman M. Surgical resection of subependymal giant cell astrocytomas (SEGAs) and changes in SEGA-related conditions: A US national claims database study. Curr. Med. Res. Opin. 28, 651-656 (2012
24. Franz DN, Leonard J, Tudor C et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann. Neurol. 59, 490-498 (2006
25. Koenig MK, Butler IJ, Northrup H. Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex. J. Child. Neurol. 23, 1238-1239 (2008
26. Jozwiak J, Jozwiak S, Oldak M. Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment. Med. Res. Rev. 26, 160-180 (2006
27. Afinitor (everolimus) tablets for oral administration, prescribing information. Novartis Pharmaceuticals Corporation, NJ, USA (2012
28. Lebwohl D, Thomas G, Lane HA et al. Research and innovation in the development of everolimus for oncology. Expert Opin. Drug Discov. 6, 323-338 (2011
29. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin. Pharmacokinet. 43, 83-95 (2004
30. Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: A new generation of mTOR inhibitors. Nat. Rev. Drug Discov. 10, 868-880 (2011
31. Kovarik JM, Hartmann S, Figueiredo J, Rouilly M, Port A, Rordorf C. Effect of rifampin on apparent clearance of everolimus. Ann. Pharmacother. 36, 981-985 (2002
32. Crowe A, Bruelisauer A, Duerr L, Guntz P, Lemaire M. Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Drug Metab. Dispos. 27, 627-632 (1999
33. O'Reilly T, McSheehy PM. Biomarker development for the clinical activity of the mTOR inhibitor everolimus (RAD001): Processes, limitations, and further proposals. Transl. Oncol. 3, 65-79 (2010
34. Lane HA, Wood JM, McSheehy PMJ et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin. Cancer Res. 15, 1612-1622 (2009
35. Beuvink I, Boulay A, Fumagalli S et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120, 747-759 (2005
36. Tanaka C, O'Reilly T, Kovarik JM et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J. Clin. Oncol. 26, 1596-1602 (2008
37. Meikle L, Pollizzi K, Egnor A et al. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: Effects on mTORC1 and Akt signaling lead to improved survival and function. J. Neurosci. 28, 5422-5432 (2008
38. Pollizzi K, Malinowska-Kolodziej I, Stumm M, Lane H, Kwiatkowski D. Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis. Mol. Cancer 8, 38 (2009
39. Boulay A, Zumstein-Mecker S, Stephan C et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res. 64, 252-261 (2004
40. Krueger DA, Care MM, Holland K et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N. Engl. J. Med. 363, 1801-1811 (2010
41. Tillema JM, Leach JL, Krueger DA, Franz DN. Everolimus alters white matter diffusion in tuberous sclerosis complex. Neurology 78, 526-531 (2012
42. Jozwiak S. Everolimus in the treatment of subependymal giant cell astrocytomas (SEGAs) associated with tuberous sclerosis complex (TSC): The EXIST-1 trial. Presented at: The 12th International Child Neurology Congress and the 11th Asian and Oceanic Congress of Child Neurology. Brisbane, Australia, 27 May-1 June 2012.
43. Yalon M, Ben-Sira L, Constantini S, Toren A. Regression of subependymal giant cell astrocytomas with RAD001 (everolimus) in tuberous sclerosis complex. Childs Nerv. Syst. 27, 179-181 (2011
44. Perek-Polnik M, Jozwiak S, Jurkiewicz E, Perek D, Kotulska K. Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex. Eur. J. Paediatr. Neurol. 16, 83-85 (2012
45. Krueger DA, Care MM, Holland K et al. Long-term safety and efficacy results from an extension phase of an open-label, prospective, Phase 1/2 trial of oral everolimus in patients with subependymal giant cell astrocytomas in tuberous sclerosis complex. Presented at: The 16th Annual Scientific Meeting of the Society for Neuro Oncology. CA, USA, 18-20 November 2011.
46. Braun M, Young J, Reiner CS, Poster D, Wuthrich RP, Serra AL. Ovarian toxicity from sirolimus. N. Engl. J. Med. 366, 1062-1064 (2012
47. Fritsche L, Budde K, Dragun D, Einecke G, Diekmann F, Neumayer HH. Testosterone concentrations and sirolimus in male renal transplant patients. Am. J. Transplant. 4, 130-131 (2004
48. Huyghe E, Zairi A, Nohra J, Kamar N, Plante P, Rostaing L. Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: An overview. Transpl. Int. 20, 305-311 (2007
49. Votubia 2.5 mg tablets, prescribing information. Novartis Europharm Limited, West Sussex, UK (2012
50. Afinitor summary of product characteristics, prescribing information. Novartis Europharm Limited, West Sussex, UK (2011